A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 4 OPEN-LABEL RANDOMIZED CONTROLLED STUDY COMPARING THE EFFECTIVENESS OF ADALIMUMAB INTRODUCTION AND METHOTREXATE DOSE ESCALATION IN SUBJECTS WITH PSORIATIC ARTHRITIS (CONTROL)

Intervention/treatment:
HUMIRA / TREXALL / RASUVO
Medical condition:
PSORIATIC ARTHRITIS
Protocol code:
M14-496
Control number:
195336
Status:
Closed
Approved:
June 23, 2016
Date Completed:
Trial phase:
Phase 4
For more information:
ClinicalTrials.gov - NCT02814175
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

Alberta

Rheumatology Research Assoc /ID# 161600
Edmonton, Alberta, T5M 0H4

British Columbia

Percuro Clinical Research, Ltd /ID# 161601
Victoria, British Columbia, V8V 3M9

Manitoba

Manitoba Clinic /ID# 151939
Winnipeg, Manitoba, R3A 1M3

Newfoundland and Labrador

St. Clare's Mercy Hospital /ID# 159680
St. John's, Newfoundland and Labrador, A1C 5B8

Ontario

Adachi Medicine Prof. Corp /ID# 152575
Hamilton, Ontario, L8N 1Y2
The Waterside Clinic /ID# 151938
Barrie, Ontario, L4M 6L2

Quebec

Ctr. de Rheum de l'est du QC /ID# 151937
Rimouski, Quebec, G5L 8W1
Groupe de Recherche en Maladies Osseuses /ID# 205693
Sainte-Foy, Quebec, G1V 3M7

Results

See the results from the trial NCT02814175. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?